Machine learning-based predictive and risk analysis using real-world data with blood biomarkers for hepatitis B patients in the malignant progression of hepatocellular carcinoma

被引:5
|
作者
Nan, Yuemin [1 ]
Zhao, Suxian [1 ]
Zhang, Xiaoxiao [1 ]
Xiao, Zhifeng [2 ]
Guo, Ruihan [3 ]
机构
[1] Hebei Med Univ, Hosp 3, Dept Tradit & Western Med Hepatol, Hebei Prov Key Lab Liver Fibrosis Chron Liver Dis, Shijiazhuang, Peoples R China
[2] Behrend Coll, Sch Engn, Penn State Erie, Erie, PA USA
[3] Shanghai Ashermed Healthcare Co Ltd, Shanghai, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷
关键词
hepatocellular carcinoma; blood biomarkers; machine learning; hepatitis B; cirrhosis; risk model; immunotherapy;
D O I
10.3389/fimmu.2022.1031400
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Hepatitis B Virus (HBV) infection may lead to various liver diseases such as cirrhosis, end-stage liver complications, and Hepatocellular carcinoma (HCC). Patients with existing cirrhosis or severe fibrosis have an increased chance of developing HCC. Consequently, lifetime observation is currently advised. This study gathered real-world electronic health record (EHR) data from the China Registry of Hepatitis B (CR-HepB) database. A collection of 396 patients with HBV infection at different stages were obtained, including 1) patients with a sustained virological response (SVR), 2) patients with HBV chronic infection and without further development, 3) patients with cirrhosis, and 4) patients with HCC. Each patient has been monitored periodically, yielding multiple visit records, each is described using forty blood biomarkers. These records can be utilized to train predictive models. Specifically, we develop three machine learning (ML)-based models for three learning tasks, including 1) an SVR risk model for HBV patients via a survival analysis model, 2) a risk model to encode the progression from HBV, cirrhosis and HCC using dimension reduction and clustering techniques, and 3) a classifier to detect HCC using the visit records with high accuracy (over 95%). Our study shows the potential of offering a comprehensive understanding of HBV progression via predictive analysis and identifies the most indicative blood biomarkers, which may serve as biomarkers that can be used for immunotherapy.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Machine learning-based survival rate prediction of Korean hepatocellular carcinoma patients using multi-center data
    Byeonggwan Noh
    Young Mok Park
    Yujin Kwon
    Chang In Choi
    Byung Kwan Choi
    Kwang il Seo
    Yo-Han Park
    Kwangho Yang
    Sunju Lee
    Taeyoung Ha
    YunKyong Hyon
    Myunghee Yoon
    BMC Gastroenterology, 22
  • [22] Machine learning-based survival rate prediction of Korean hepatocellular carcinoma patients using multi-center data
    Noh, Byeonggwan
    Park, Young Mok
    Kwon, Yujin
    Choi, Chang In
    Choi, Byung Kwan
    Seo, Kwang Il
    Park, Yo-Han
    Yang, Kwangho
    Lee, Sunju
    Ha, Taeyoung
    Hyon, YunKyong
    Yoon, Myunghee
    BMC GASTROENTEROLOGY, 2022, 22 (01)
  • [23] The biomedical knowledge graph of symptom phenotype in coronary artery plaque: machine learning-based analysis of real-world clinical data
    Huan, Jia-Ming
    Wang, Xiao-Jie
    Li, Yuan
    Zhang, Shi-Jun
    Hu, Yuan-Long
    Li, Yun-Lun
    BIODATA MINING, 2024, 17 (01):
  • [24] MACHINE LEARNING-BASED CLASSIFICATION OF HBV AND HCV-RELATED HEPATOCELLULAR CARCINOMA USING GENOMIC BIOMARKERS br
    Akbulut, Sami
    Kucukakcali, Zeynep
    Colak, Cemil
    JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESI DERGISI, 2022,
  • [25] Enhancing malignant transformation predictions in oral potentially malignant disorders: A novel machine learning framework using real-world data
    Li, Jing Wen
    Zhang, Meng Jing
    Zhou, Ya Fang
    Adeoye, John
    Pu, Jing Ya Jane
    Thomson, Peter
    Mcgrath, Colman Patrick
    Zhang, Dian
    Zheng, Li Wu
    ISCIENCE, 2025, 28 (03)
  • [26] Population Pharmacokinetic Modeling of Lenvatinib in Chinese Patients With Advanced Hepatocellular Carcinoma Using Real-World Data
    Hu, Yingying
    Chen, Ruijia
    Ye, Zhenjie
    Wei, Fuqun
    Lin, Kecan
    Liu, Jingfeng
    Zeng, Yongyi
    JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 62 (12): : 1507 - 1517
  • [27] Real-world risk score for hepatocellular carcinoma (RWS-HCC): a clinically practical risk predictor for HCC in chronic hepatitis B
    Poh, Zhongxian
    Shen, Liang
    Yang, Hwai-I
    Seto, Wai-Kay
    Wong, Vincent W.
    Lin, Clement Y.
    Goh, Boon-Bee George
    Chang, Pik-Eu Jason
    Chan, Henry Lik-Yuen
    Yuen, Man-Fung
    Chen, Chien-Jen
    Tan, Chee-Kiat
    GUT, 2016, 65 (05) : 887 - 888
  • [28] Real-world data in patients with hepatocellular carcinoma treated with transarterial chemoembolization: the second interim analysis of OPTIMIS
    Peck-Radosavljevic, M.
    Kudo, M.
    Lee, H. C.
    Cheng, A. -Lii
    Nakajima, K.
    Raoul, J. -L.
    JOURNAL OF HEPATOLOGY, 2018, 68 : S202 - S202
  • [29] Using Machine Learning Applied to Real-World Healthcare Data for Predictive Analytics: An Applied Example in Bariatric Surgery
    Johnston, Stephen S.
    Morton, John M.
    Kalsekar, Iftekhar
    Ammann, Eric M.
    Hsiao, Chia-Wen
    Reps, Jenna
    VALUE IN HEALTH, 2019, 22 (05) : 580 - 586
  • [30] Utilization of Antiviral Therapy for Patients With Hepatitis B-Related Hepatocellular Carcinoma: A Nationwide Real-World US Study
    Kudaravalli, Sahith
    Kam, Leslie Y.
    Huang, Daniel Q.
    Cheung, Ramsey
    Nguyen, Mindie H.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2023, 21 (13) : 3305 - 3313.e4